ArticleOncogene2013
Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 65 citations in OpenAlex.
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
- Malignant Pleural Effusion: Palliative Managements and Indication for Pleurodesis Based on Survival Scores.Journal of surgical oncology · 2025Review
- Signaling networks in cancer stromal senescent cells establish malignant microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Assessment of Angiogenic Properties of Malignant Pleural Effusion (MPE) Fluid.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Targeting of TAMs: can we be more clever than cancer cells?Cellular & molecular immunology · 2024Review
- Single-cell RNA sequencing reveals epithelial cells driving brain metastasis in lung adenocarcinoma.iScience · 2024Article
- Malignant pleural effusion: current understanding and therapeutic approach.Respiratory research · 2024Review
- Malignant pleural disease.Breathe (Sheffield, England) · 2023Review
- Role of osteopontin in cancer development and treatment.Heliyon · 2023Review
- Reprogramming the tumor microenvironment leverages CD8Molecular therapy oncolytics · 2023Article
- Review
- Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure.Science advances · 2022Article
- The role of angiogenesis in malignant pleural effusion: from basic research to clinical application.American journal of cancer research · 2022Review
- Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Osteopontin Deficiency Ameliorates Prostatic Fibrosis and Inflammation.International journal of molecular sciences · 2021Article
- Experimental Babesia rossi infection induces hemolytic, metabolic, and viral response pathways in the canine host.BMC genomics · 2021Article
- Efferocytosis fuels malignant pleural effusion through TIMP1.Science advances · 2021Article
- New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis.Cancers · 2021Review
- Distinct JNK/VEGFR signaling on angiogenesis of breast cancer-associated pleural fluid based on hormone receptor status.Cancer science · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted phosphoprotein-1 (SPP1) promotes cancer cell survival and regulates tumor-associated angiogenesis and inflammation, both central to the pathogenesis of malignant pleural effusion (MPE). Here, we examined the impact of tumor- and host-derived SPP1 in MPE formation and explored the mechanisms by which the cytokine exerts its effects. We used a syngeneic murine model of lung adenocarcinoma-induced MPE. To dissect the effects of tumor- versus host-derived SPP1, we intrapleurally injected wild-type and SPP1-knockout C57/BL/6 mice with either wild-type or SPP1-deficient syngeneic lung cancer cells. We demonstrated that both tumor- and host-derived SPP1 promoted pleural fluid accumulation and tumor dissemination in a synergistic manner (P<0.001). SPP1 of host origin elicited macrophage recruitment into the cancer-affected pleural cavity and boosted tumor angiogenesis, whereas tumor-derived SPP1 curtailed cancer cell apoptosis in vivo. Moreover, the cytokine directly promoted vascular hyper-permeability independently of vascular endothelial growth factor. In addition, SPP1 of tumor and host origin differentially affected the expression of proinflammatory and angiogenic mediators in the tumor microenvironment. These results suggest that SPP1 of tumor and host origin impact distinct aspects of MPE pathobiology to synergistically promote pleural fluid formation and pleural tumor progression. SPP1 may present an attractive target of therapeutic interventions for patients with MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.